EP0569426A1 - Oral compositions containing bromochlorophene and zinc ions - Google Patents

Oral compositions containing bromochlorophene and zinc ions

Info

Publication number
EP0569426A1
EP0569426A1 EP19920903676 EP92903676A EP0569426A1 EP 0569426 A1 EP0569426 A1 EP 0569426A1 EP 19920903676 EP19920903676 EP 19920903676 EP 92903676 A EP92903676 A EP 92903676A EP 0569426 A1 EP0569426 A1 EP 0569426A1
Authority
EP
European Patent Office
Prior art keywords
composition
bromochlorophene
weight
zinc
zinc ions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920903676
Other languages
German (de)
French (fr)
Inventor
Ian Marlow
Nicholas Moody
John Hamilton Pullen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boots Co PLC
Original Assignee
Boots Co PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boots Co PLC filed Critical Boots Co PLC
Publication of EP0569426A1 publication Critical patent/EP0569426A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27Zinc; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34Alcohols
    • A61K8/347Phenols

Definitions

  • the cr ⁇ sen invention relates ;o oral coir ⁇ ositior.s which comprise at least two active ingre.diencs selected from agencs which decrease the sensitivity of teeth, 5. anti-plaque agencs and anti-tarcar agents. Beneficial effects are obtained by combining two or more active ingredients within a single composition.
  • compositions containing ar.ti-plaque agents are well known to those skilled in the arc.
  • Typical an i- 0 plaque agents include cationic antibacterial materials such as chlorhexidine and non-cationic compounds such as phenol derivatives.
  • Preferred anti-plaque agencs are non-cationic compounds, for example, bromochlorophene, triclosan, hexachlorophene and dichiorophene.
  • Anti-tartar agents are also well known and include zinc salts such as zinc citrate (also known to have anti-plaque activity) and various polyphosphates .
  • the present invention provides oral C compositions which comprise bromochlorophene and zinc ions in a weight :weight ratio in the range of 1:0.1 tc
  • the bromochlorophene generally comprises 0.002 to 2%, preferably 0.01 to 2%, preferably 0.01 to 0.5%, suitably 0.05 to 0.2%, preferably .about 0.1% by weight of the composition.
  • Zinc ions generally comprise 0.0005 to , 2%, preferably 0.02 to 2% preferably 0.1 to 1%, preferably about 0.155% by weight of the composition.
  • Zinc ions are generally provided in the form of pharmaceutically acceptable zinc salts such as zinc citrate, zinc chloride, zinc sulphate, zinc acetate, zinc laccate, zinc saiicylate, zinc thiocyanate, zinc giucoheptanoate, zinc giuconate, zinc aieate, zinc f marate or mixtures thereof.
  • zinc ions are provided in the form of zinc citrate which may comprise 0.05 to 4%, preferably 0.2 to 4%, most preferably 0.3 to 3% by weight of the composition.
  • the oral composition may be in the form of, for example, a dentifrice, mouthwash, toothpowder, chewing gum, lozenge, denture cleanser or toothbrush sanitiser.
  • Such compositions may contain conventional base materials such as, for example, humectants, surfactants, e ulsifiers, gelling agents e.g. cellulose gum, xanthan gum, hydroxyethyl cellulose, carrageenan and alginates, and abrasives and may be formulated in a known manner.
  • Further optional ingredients may be added if desired, for example, fluoride salts, flavourings, colourings, sweeteners, preservatives and alcohol.
  • a fluoride-containing substance such as sodium monofluorophosphate, sodium fluoride, or an organic a ine fluoride.
  • a fluoride-containing substance such as sodium monofluorophosphate, sodium fluoride, or an organic a ine fluoride.
  • Such components are typically added in amounts of between 0.01% and 5% by weight of the composition.
  • sodium monofluorophosphate may suitably be included in a dentifrice formulation in an amount of about 1% by weight
  • sodium fluoride may be included in a mouthwash formulation in an amount of about 0.05% by weigh .
  • concentrations of bromochlorophene and zinc citrate may be varied within the limits described above as appropriate to the particular type of formulation prepared.
  • mouthwash formulations will typically contain bromochlorophene at concentrations about ten times lower than those used in toothpastes/dentifrices.
  • the oral compositions according to the invention may also contain conventional ingredients which decrease the sensitivity of teeth. These ingredients are usually included to between 1 and 15% by weight of the composition and include, for example, potassium salts such as potassium citrate, potassium chloride and potassium nitrate, strontium salts such as strontium chloride and strontium acetate, and formaldehyde.
  • potassium salts such as potassium citrate, potassium chloride and potassium nitrate
  • strontium salts such as strontium chloride and strontium acetate
  • formaldehyde may comprise 5 to 15%, suitably about 10% by weight of the composition whilst potassium nitrate may comprise 2 to 10%, suitably about 5% by weight, and formaldehyde may comprise 0.5 to 5%, suitably about 1.3% by weight of the composition.
  • compositions according to the invention are dentifrices which further comprise a dentally acceptable abrasive.
  • Typical dentally acceptable abrasives include alumina, silica, synthetic resins and mixtures thereof.
  • Preferred compositions contain one or more silica blends having abrasive and/or thickening properties.
  • Preferred abrasives are non-crystalline silica abrasives, particularly in the form of precipitated silica or milled silica gels available commercially for example under the trade names" Zeodent
  • Preferred dentifrice compositions according to the invention comprise 5% to 50%, more preferably 15% to 30% by weight of silica.
  • the anti-plaque activity of t the compositions according to the present invention has been demonstrated as fellows. Thin strips of aluminium were used as "artificial tooth" surfaces on which plaque, collected from a small number of donors, was grown. Growth was encouraged by the provision of conditions resembling a normal oral environment (saliva, nutrients, pH and temperature) over a two day period with simulations made of the intake of two meals and of a sleeping, low nutrient period. The aluminium strips (and plaque) were exposed for one minute on two occasions to a solution of the composition to be tested with distilled water and fresh saliva, thus simulating evening and morning toothbrushing sessions. Following the second exposure, plaque remaining on the strips after a four hour growth period and subsequent rinsing was dispersed by ultrasonic vibration. The optical density of the resulting plaque suspensions at 570 nm (two replicate readings per strip) were used to estimate the percentage reduction in plaque growth compared to plaque growth on test strips exposed to a control composition of saliva and water.
  • Titanium dioxide (sold under the trade designation PH EUR) 0.75 5) Sodium saccharin BP 0.26 % w/w
  • Sorbitol solution (component 1) and water were mixed together.
  • the base formulation was made up containing 0.1% w/w bromochlorophene (dissolved in flavouring and added at Stage 4) and 0.5% w/w zinc citrate trihydrate (added at Stage 3) to give the toothpaste of Example 1.
  • Examp e 2 The base formulation was made up containing 0.1% w/w bromochlorophene (dissolved in flavouring and added at Stage 4) and 0.5% w/w zinc citrate trihydrate (added at Stage 3) to give the toothpaste of Example 1.
  • the base formulation was made up containing 0.1% w/w bromochlorophene (dissolved in flavouring and added at Stage 4) and 2.0% w/w zinc citrate trihydrate (added at Stage 3) to give the toothpaste of Example 2.
  • Examples 1 and 2 were compared to those of the base formulation containing 0.1% w/w bromochlorophene alone and to a proprietcry brand of toothpaste containing 0.2% triclosan and 0.5% zinc citrate.
  • Study 1 employed six aluminium strips for each- treatment group and two absorbance readings were taken per sample. The percentage reduction in amount of plaque present compared to the control (saliva and water) are shown in Table 1.
  • Table 1 Non-parametric Kruskal- Wallis analysis of variance, followed by Miller's Multiple Comparison technique, shows there was a statistically significant reduction in plaque level on strips treated with the toothpaste of Examples 1 and 2, containing 0.1% bromochlorophene and 0.5% zinc citrate and 0.1% bromochlorophene and 2% zinc citrate respectively, when compared to the control. There was no statistically significant difference between plaque level on control strips and plaque level on strips exposed to . toothpastes containing either 0.1% bromochlorophene or 0.2% triclosan and 0.5% zinc citrate. Table 1
  • the anti-plaque activity of the formulation of Example 1 was compared to those of the base formulation containing 0.1% bromochlorophene alone or containing 0.2% triclosan (dissolved in flavouring and added at Stage 4) and 0.5% zinc citrate.
  • Study 2 employed ten aluminium strips for each treatment group. The percentage reduction in amount of plaque present compared to the control (saliva and water) are shown in Table 2. Bartlett's test for homogeneity of variances between groups indicated that parametric analysis of the results obtained was justified. Parametric one-way analysis of variance, followed by a Tukey Multiple Range test, shows there was a statistically significant reduction in plaque levels on strips treated with the toothpaste of Example 1, containing 0.1% bromochlorophene and 0.5% zinc .citrate, when compared to the control. There was no statistically significant difference between plaque level on control strips and plaque level on strips exposed to toothpastes containing either 0.1% bromochlorophene or 0.2% triclosan and 0.5% zinc citrate.
  • the antiplaque activity of the formulation of Example 1 was compared to those of the base formulation containing 0.1% bromochlorophene alone or containing 0.5% zinc citrate.
  • Study 3 employed six aluminium strips for each treatment group. The percentage reduction in amount of plaque present compared to the control (saliva and water) are shown in Table 3.
  • Table 3 Non-parametric Kruskal- Wallis analysis of variance, followed by Miller's Multiple Comparison technique, shows there was a statistically significant reduction in plaque level on strips treated with the toothpaste of Example 1, containing 0.1% bromochlorophene and 0.5% zinc citrate, and a toothpaste comprising the toothpaste base . and 0.1% bromochlorophene alone. There was no significant difference between plaque level on control strips and plaque level on strips exposed to toothpaste containing 0.5% zinc citrate.
  • Toothpastes are prepared in conventional manner, having the following formulations :
  • Toothpastes are prepared in conventional manne: having the -following for ulations:
  • the base formulation was made up containing 9.44% w/w silica (sold under the trade name Zeodent 113) to give the toothpaste of Example 7.
  • a mouthwash was " prepared in conventional manne: having the following formulation: w/w
  • Polysorbate 20 (sold under the trade name
  • a toothpaste was prepared in conventional manner having the following formulation:
  • Zinc citrate trihydrate 0.5 Titanium dioxide PH EUR 0.75

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Cosmetics (AREA)

Abstract

Compositions destinées à l'hygiène buccale contenant à la fois du bromochlorophène et des ions de zinc, dans un rapport pondéral de 1:01 à 1:50. La combinaison de ces composants a un effet synergique antiplaque. Ces compositions peuvent revêtir la forme, par exemple, de pâte dentifrice, de collutoire, de poudre dentifrice, de gomme à mâcher ou de pastilles.Compositions for oral hygiene containing both bromochlorophene and zinc ions, in a weight ratio of 1:01 to 1:50. The combination of these components has a synergistic anti-plaque effect. These compositions can take the form, for example, of toothpaste, mouthwash, tooth powder, chewing gum or lozenges.

Description

ι -
ORAL COMPOSITIONS CONTAINING BROMOCHLOROPHENE AND
ZINC IONS
The crεsen invention relates ;o oral coirøositior.s which comprise at least two active ingre.diencs selected from agencs which decrease the sensitivity of teeth, 5. anti-plaque agencs and anti-tarcar agents. Beneficial effects are obtained by combining two or more active ingredients within a single composition.
Oral compositions containing ar.ti-plaque agents are well known to those skilled in the arc. Typical an i- 0 plaque agents include cationic antibacterial materials such as chlorhexidine and non-cationic compounds such as phenol derivatives. Preferred anti-plaque agencs are non-cationic compounds, for example, bromochlorophene, triclosan, hexachlorophene and dichiorophene.
5 Anti-tartar agents are also well known and include zinc salts such as zinc citrate (also known to have anti-plaque activity) and various polyphosphates .
Surprisingly, the applicants have found an entirely unexpected advantage may be obtained by combining the 0 known active ingredients bromochlorophene and zinc ions within a single oral health composition. Combinations of active ingredients are known in the art, see for example EP-161899 which discloses toothpaste compositions containing triclosan and zinc citrate. 5 However, the applicants have found that specific combinations of bromochlorophene and zinc ions provide a synergistic anti-plaque effect which is not provided by the prior art compositions.
Thus the present invention provides oral C compositions which comprise bromochlorophene and zinc ions in a weight :weight ratio in the range of 1:0.1 tc
1:50, preferably 1:1 to 1:10, more preferably 1:1.3 to 1:8, preferably 1:1.5 to 1:8. The bromochlorophene generally comprises 0.002 to 2%, preferably 0.01 to 2%, preferably 0.01 to 0.5%, suitably 0.05 to 0.2%, preferably .about 0.1% by weight of the composition. Zinc ions generally comprise 0.0005 to , 2%, preferably 0.02 to 2% preferably 0.1 to 1%, preferably about 0.155% by weight of the composition.
Zinc ions are generally provided in the form of pharmaceutically acceptable zinc salts such as zinc citrate, zinc chloride, zinc sulphate, zinc acetate, zinc laccate, zinc saiicylate, zinc thiocyanate, zinc giucoheptanoate, zinc giuconate, zinc aieate, zinc f marate or mixtures thereof. Preferably zinc ions are provided in the form of zinc citrate which may comprise 0.05 to 4%, preferably 0.2 to 4%, most preferably 0.3 to 3% by weight of the composition.
The oral composition may be in the form of, for example, a dentifrice, mouthwash, toothpowder, chewing gum, lozenge, denture cleanser or toothbrush sanitiser. Such compositions may contain conventional base materials such as, for example, humectants, surfactants, e ulsifiers, gelling agents e.g. cellulose gum, xanthan gum, hydroxyethyl cellulose, carrageenan and alginates, and abrasives and may be formulated in a known manner. Further optional ingredients may be added if desired, for example, fluoride salts, flavourings, colourings, sweeteners, preservatives and alcohol.
It is often desirable to add a fluoride-containing substance, such as sodium monofluorophosphate, sodium fluoride, or an organic a ine fluoride. Such components are typically added in amounts of between 0.01% and 5% by weight of the composition. For example, sodium monofluorophosphate may suitably be included in a dentifrice formulation in an amount of about 1% by weight, and sodium fluoride may be included in a mouthwash formulation in an amount of about 0.05% by weigh .
The concentrations of bromochlorophene and zinc citrate may be varied within the limits described above as appropriate to the particular type of formulation prepared. For example, as a result of the relatively low solubility of bromochlorophene in water, mouthwash formulations will typically contain bromochlorophene at concentrations about ten times lower than those used in toothpastes/dentifrices.
The oral compositions according to the invention may also contain conventional ingredients which decrease the sensitivity of teeth. These ingredients are usually included to between 1 and 15% by weight of the composition and include, for example, potassium salts such as potassium citrate, potassium chloride and potassium nitrate, strontium salts such as strontium chloride and strontium acetate, and formaldehyde. For example, strontium chloride may comprise 5 to 15%, suitably about 10% by weight of the composition whilst potassium nitrate may comprise 2 to 10%, suitably about 5% by weight, and formaldehyde may comprise 0.5 to 5%, suitably about 1.3% by weight of the composition.
Preferred compositions according to the invention are dentifrices which further comprise a dentally acceptable abrasive. Typical dentally acceptable abrasives include alumina, silica, synthetic resins and mixtures thereof. Preferred compositions contain one or more silica blends having abrasive and/or thickening properties. Preferred abrasives are non-crystalline silica abrasives, particularly in the form of precipitated silica or milled silica gels available commercially for example under the trade names" Zeodent
(Zeofinn OY) and Syloblanc (Grace) respectively. Preferred dentifrice compositions according to the invention comprise 5% to 50%, more preferably 15% to 30% by weight of silica.
The anti-plaque activity of tthe compositions according to the present invention has been demonstrated as fellows. Thin strips of aluminium were used as "artificial tooth" surfaces on which plaque, collected from a small number of donors, was grown. Growth was encouraged by the provision of conditions resembling a normal oral environment (saliva, nutrients, pH and temperature) over a two day period with simulations made of the intake of two meals and of a sleeping, low nutrient period. The aluminium strips (and plaque) were exposed for one minute on two occasions to a solution of the composition to be tested with distilled water and fresh saliva, thus simulating evening and morning toothbrushing sessions. Following the second exposure, plaque remaining on the strips after a four hour growth period and subsequent rinsing was dispersed by ultrasonic vibration. The optical density of the resulting plaque suspensions at 570 nm (two replicate readings per strip) were used to estimate the percentage reduction in plaque growth compared to plaque growth on test strips exposed to a control composition of saliva and water.
Typical compositions are illustrated in Examples 1 to 6 hereinafter.
Toothpaste base formulation
% w/w
1) Sorbitol (70% solution) 50 2) Sodium monofluorophosphate 0.84
3) Sodium lauryl sulphate (sold under the trade name Empicol LZ) 1.5
4) Titanium dioxide (sold under the trade designation PH EUR) 0.75 5) Sodium saccharin BP 0.26 % w/w
6) Silica (sold under the trade name Zeodent 113) 12.22
7) Silic (sold under the trade name Zeodent 163) 8.33
8) Sodium carboxymethylcelluiose
(sold under the trade name Walccel CRT 2000 PA) 0.9
9) Flavouring 1.0 v 10) Water ad. 100
1. Sorbitol solution (component 1) and water were mixed together.
2. Components 2 and 5 were added and the mixture stirred until dissolved.
3. Components 3, 4, 6, 7 and 8 were added' and the mixture was mixed thoroughly under vacuum until a smooth paste was formed.
4. Flavouring (component 9) was mixed in under vacuum and the composition was dearated to give the toothpaste base formulation.
Example 1
The base formulation was made up containing 0.1% w/w bromochlorophene (dissolved in flavouring and added at Stage 4) and 0.5% w/w zinc citrate trihydrate (added at Stage 3) to give the toothpaste of Example 1. Examp e 2
The base formulation was made up containing 0.1% w/w bromochlorophene (dissolved in flavouring and added at Stage 4) and 2.0% w/w zinc citrate trihydrate (added at Stage 3) to give the toothpaste of Example 2.
Stu v 1
The anti-plaque activity of the formulations of
Examples 1 and 2 were compared to those of the base formulation containing 0.1% w/w bromochlorophene alone and to a proprietcry brand of toothpaste containing 0.2% triclosan and 0.5% zinc citrate.
Study 1 employed six aluminium strips for each- treatment group and two absorbance readings were taken per sample. The percentage reduction in amount of plaque present compared to the control (saliva and water) are shown in Table 1. Non-parametric Kruskal- Wallis analysis of variance, followed by Miller's Multiple Comparison technique, shows there was a statistically significant reduction in plaque level on strips treated with the toothpaste of Examples 1 and 2, containing 0.1% bromochlorophene and 0.5% zinc citrate and 0.1% bromochlorophene and 2% zinc citrate respectively, when compared to the control. There was no statistically significant difference between plaque level on control strips and plaque level on strips exposed to . toothpastes containing either 0.1% bromochlorophene or 0.2% triclosan and 0.5% zinc citrate. Table 1
Studv 2
The anti-plaque activity of the formulation of Example 1 was compared to those of the base formulation containing 0.1% bromochlorophene alone or containing 0.2% triclosan (dissolved in flavouring and added at Stage 4) and 0.5% zinc citrate.
Study 2 employed ten aluminium strips for each treatment group. The percentage reduction in amount of plaque present compared to the control (saliva and water) are shown in Table 2. Bartlett's test for homogeneity of variances between groups indicated that parametric analysis of the results obtained was justified. Parametric one-way analysis of variance, followed by a Tukey Multiple Range test, shows there was a statistically significant reduction in plaque levels on strips treated with the toothpaste of Example 1, containing 0.1% bromochlorophene and 0.5% zinc .citrate, when compared to the control. There was no statistically significant difference between plaque level on control strips and plaque level on strips exposed to toothpastes containing either 0.1% bromochlorophene or 0.2% triclosan and 0.5% zinc citrate.
Table 2
Studv 3
The antiplaque activity of the formulation of Example 1 was compared to those of the base formulation containing 0.1% bromochlorophene alone or containing 0.5% zinc citrate.
Study 3 employed six aluminium strips for each treatment group. The percentage reduction in amount of plaque present compared to the control (saliva and water) are shown in Table 3. Non-parametric Kruskal- Wallis analysis of variance, followed by Miller's Multiple Comparison technique, shows there was a statistically significant reduction in plaque level on strips treated with the toothpaste of Example 1, containing 0.1% bromochlorophene and 0.5% zinc citrate, and a toothpaste comprising the toothpaste base .and 0.1% bromochlorophene alone. There was no significant difference between plaque level on control strips and plaque level on strips exposed to toothpaste containing 0.5% zinc citrate.
Table 3
Examples 3 and 4
Toothpastes are prepared in conventional manner, having the following formulations :
Sorbitol (70% solution)
Potassium Nitrate
Sodium Monofluorophosphate
Silica
Sodium Lauryl Sulphate
Zinc citrate trihydrate
Titanium Dioxide
Sodium Methyl Cocoyl Taurate
Bromochlorophene
Cellulose Gum
Preservative
Flavour & Saccharin
Colour
Water Examples 5 and
Toothpastes are prepared in conventional manne: having the -following for ulations:
Ex. iX.
% w/w
Sorbitoi (70% solution) 25
Sodium Monofluorophosphate
Silica 22.5
Sodium Lauryl Sulphate
Zinc citrate trihydrate 0.5
Titanium Dioxide 0.96
Sodium Methyl Cocoyl Taurate 1.19
Bromochlorophene 0.1
Cellulose Gum 0.5
Preservative 0.1
Flavour &. Saccharin 1.2
Colour q.s.
Polyethylene glycol 400 3
Strontium chloride hexahydrat- 10
Water to 100 to 100
Example 7
The base formulation was made up containing 9.44% w/w silica (sold under the trade name Zeodent 113) to give the toothpaste of Example 7.
Example 8
A mouthwash was " prepared in conventional manne: having the following formulation: w/w
Hydroxyethylcellulose (sold under the trade name Natrosol 250 HR)
Dehydrated alcohol BP Flavour
Polysorbate 20 (sold under the trade name
Tween 20) 0.15
Polyethylene giycol - 40 Hydrogenated castor oil
(sold under the trade name Croduret 40) 0.15 Sodium saccharin BP 0.04
Sodium fluoride 0.05
Glycerin BP 4.00
Bromochlorophene 0.02
Zinc citrate trihydrate . 0.1 Sodium lauryl sulphate 0.75
Sorbitol (70% solution) 11.00
Polyethylene giycol - 400 5.00
Propylene giycol 5.00
Purified water BP to 100
Example 9
A toothpaste was prepared in conventional manner having the following formulation:
% w/w
Sorbitol (70% solution) 50 Sodium monofluorophosphate 0.84
Silica 21.66
Sodium lauryl sulphate 1.5
Sodium hydroxide BP 0.2
Zinc citrate trihydrate 0.5 Titanium dioxide PH EUR 0.75
Bromochlorophene 0.1
Sodium carboxymethylcellulose 0.9
Flavour 1.Ov
Sodium saccharin BP 0.26 Purified water BP to 100

Claims

Claims
1. An oral composition comprising bromochlorophene and zinc ions in a weight: eight ratio in the range of 1:0.1 to 1:50.
2. A composition as claimed in Claim 1 wherein the weight:weight ratio of bromochlorophene to zinc ions is 1:1 to 1:10.
3. A composition as claimed in Claim 2 wherein the weightrweight ratio of bromochlorophene to zinc ions is 1:1.3 to 1:8.
4. A composition as claimed in Claim 3 which comprises 0.002 to 2% by weight bromochlorophene.
5. A composition as claimed in Claim 4 which comprises 0.01 to 2% by weight bromochlorophene.
6. A composition as claimed in any one of the preceding claims which comprises 0.005 to 2% by weight zinc ions.
7. A composition as claimed in Claim 6 which comprises 0.02 to 2% by weight zinc ions.
8. A composition as claimed in any one of the preceding claims which comprises zinc citrate.
9. A composition as claimed in Claim 8 which comprises 0.01 to 4% by weight zinc citrate.
10. A composition as claimed in Claim 9 which comprises 0.05 to 4% by weight zinc citrate.
11. A co postion as claimed in any one of the preceding claims which comprises an ingredient which decreases the sensitivicv of teeth.
12. A composition as claimed in any one of the preceding claims in the form of a dentifrice which comprises a dentally acceptable abrasive.
13. A method of cleansing the mouth for cosmetic purposes by application of a composition as claimed in any one of the preceding claims .
14. A method for prophylaxis or treatment of gum disease or dental caries by application of a composition as claimed in any one of Claims 1 to 12.
15. The use of a composition as claimed in any one of Claims 1 to 12 in the prophylaxis or treatment of gum disease or dental caries.
16. The use of a composition as claimed in any one of Claims 1 to 12 in the manufacture of a medicament for the prophylaxis or treatment of gum disease or dental caries.
EP19920903676 1991-02-02 1992-02-03 Oral compositions containing bromochlorophene and zinc ions Ceased EP0569426A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919102293A GB9102293D0 (en) 1991-02-02 1991-02-02 Oral compositions
GB9102293 1991-02-02

Publications (1)

Publication Number Publication Date
EP0569426A1 true EP0569426A1 (en) 1993-11-18

Family

ID=10689451

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19920903676 Ceased EP0569426A1 (en) 1991-02-02 1992-02-03 Oral compositions containing bromochlorophene and zinc ions

Country Status (4)

Country Link
EP (1) EP0569426A1 (en)
AU (1) AU1181592A (en)
GB (1) GB9102293D0 (en)
WO (1) WO1992013514A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007269702B2 (en) * 2006-06-30 2011-07-21 Vonage Network Llc Method and apparatus for visual message indication in a VOIP system

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020238A1 (en) * 1997-10-23 1999-04-29 Warner-Lambert Company Metal ion-containing oral products with reduced astringency

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8411731D0 (en) * 1984-05-09 1984-06-13 Unilever Plc Oral compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9213514A1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007269702B2 (en) * 2006-06-30 2011-07-21 Vonage Network Llc Method and apparatus for visual message indication in a VOIP system

Also Published As

Publication number Publication date
AU1181592A (en) 1992-09-07
WO1992013514A1 (en) 1992-08-20
GB9102293D0 (en) 1991-03-20

Similar Documents

Publication Publication Date Title
EP0803243B1 (en) Cyclodextrins and phenolic compounds in dental products
CN1107493C (en) Antiseptic dentifrice
US4146607A (en) Synergistic anti-plaque mixture with tetradecylamine plus aluminum and/or zinc
CA1255606A (en) Oral hygiene compositions
US6261540B1 (en) Cyclodextrins and hydrogen peroxide in dental products
WO1994014406A1 (en) Oral compositions containing antiplaque, anticalculus agents
US4272512A (en) Antigingivitis composition
JPH0967237A (en) Abradant system and surfactant system-based composition
WO1994014407A1 (en) Oral compositions containing antiplaque, anticalculus agents
EA001791B1 (en) Dentrifice composition
US5085850A (en) Anti-plaque compositions comprising a combination of morpholinoamino alcohol and metal salts
GB2191092A (en) Antiplaque oral composition
US4853213A (en) Use of periwinkle in oral hygiene
SK582000A3 (en) Oral and dental hygiene products for sensitive teeth
US20040258631A1 (en) Oral care compositions exhibiting antiplaque and breath freshening properties
EP1595537A1 (en) Buccal cavity treatment composition and corresponding uses thereof
EP0569426A1 (en) Oral compositions containing bromochlorophene and zinc ions
GB2210265A (en) Dentifrice compositions
CA1327016C (en) Oral cleansing preparation
CA2300205A1 (en) Compositions for inhibiting gingivitis
AU2003204913B2 (en) Cyclodextrins in Dental Products
AU7164500A (en) Cyclodextrins in dental products
AU2006201901A1 (en) Cyclodextrins in dental products
MXPA97002980A (en) Ciclodextrinas in denta products
KR20070102184A (en) Oral composition with improved antimicrobial property

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930723

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL

17Q First examination report despatched

Effective date: 19931130

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19950316